Lenox Wealth Management Inc. Has $908,000 Position in Novartis AG (NVS)
Lenox Wealth Management Inc. increased its stake in shares of Novartis AG (NYSE:NVS) by 6.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,585 shares of the company’s stock after buying an additional 683 shares during the quarter. Lenox Wealth Management Inc.’s holdings in Novartis were worth $908,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of the stock. Farr Miller & Washington LLC DC increased its holdings in Novartis by 0.3% during the 2nd quarter. Farr Miller & Washington LLC DC now owns 2,959 shares of the company’s stock valued at $247,000 after purchasing an additional 10 shares in the last quarter. FCG Advisors LLC lifted its holdings in shares of Novartis by 0.3% in the second quarter. FCG Advisors LLC now owns 4,271 shares of the company’s stock valued at $357,000 after purchasing an additional 12 shares in the last quarter. Ledyard National Bank lifted its holdings in shares of Novartis by 0.9% in the second quarter. Ledyard National Bank now owns 3,428 shares of the company’s stock valued at $286,000 after purchasing an additional 30 shares in the last quarter. Parkside Financial Bank & Trust lifted its holdings in shares of Novartis by 0.7% in the second quarter. Parkside Financial Bank & Trust now owns 4,492 shares of the company’s stock valued at $375,000 after purchasing an additional 31 shares in the last quarter. Finally, Brookstone Capital Management lifted its holdings in shares of Novartis by 1.1% in the second quarter. Brookstone Capital Management now owns 2,930 shares of the company’s stock valued at $245,000 after purchasing an additional 31 shares in the last quarter. Institutional investors and hedge funds own 10.87% of the company’s stock.
Novartis AG (NVS) traded down $0.66 during trading hours on Thursday, hitting $83.18. The company had a trading volume of 1,256,800 shares, compared to its average volume of 2,275,874. The company has a current ratio of 1.08, a quick ratio of 0.81 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $198,331.47, a P/E ratio of 17.65, a P/E/G ratio of 2.67 and a beta of 0.73. Novartis AG has a twelve month low of $66.93 and a twelve month high of $86.90.
Novartis (NYSE:NVS) last released its earnings results on Tuesday, October 24th. The company reported $1.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.25 by $0.04. The business had revenue of $12.41 billion for the quarter, compared to the consensus estimate of $12.21 billion. Novartis had a return on equity of 15.77% and a net margin of 13.73%. Novartis’s quarterly revenue was up 2.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.23 earnings per share. research analysts anticipate that Novartis AG will post 4.75 EPS for the current year.
NVS has been the topic of a number of research reports. Cowen set a $90.00 price target on Novartis and gave the company a “hold” rating in a report on Wednesday, August 9th. BidaskClub lowered Novartis from a “hold” rating to a “sell” rating in a report on Friday, August 11th. J P Morgan Chase & Co restated a “neutral” rating on shares of Novartis in a report on Tuesday, August 29th. Zacks Investment Research upgraded Novartis from a “hold” rating to a “buy” rating and set a $96.00 price target on the stock in a report on Tuesday, September 19th. Finally, Leerink Swann boosted their price target on Novartis from $89.00 to $91.00 and gave the company a “market perform” rating in a report on Monday, October 23rd. Four analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have assigned a buy rating to the company. Novartis currently has a consensus rating of “Hold” and a consensus target price of $85.32.
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.